Diabetes mellitus is an important risk factor for a first cardiovascular event and for worse outcomes after a cardiovascular event has occurred. This situation might be caused, at least in part, by the prothrombotic status observed in patients with diabetes. Therefore, contemporary antithrombotic strategies, including more potent agents or drug combinations, might provide greater clinical benefit in patients with diabetes than in those without diabetes. In this Consensus Statement, our Working Group explores the mechanisms of platelet and coagulation activity, the current debate on antiplatelet therapy in primary cardiovascular disease prevention, and the benefit of various antithrombotic approaches in secondary prevention of cardiovascular disease in patients with diabetes. While acknowledging that current data are often derived from underpowered, observational studies or subgroup analyses of larger trials, we propose antithrombotic strategies for patients with diabetes in various cardiovascular settings (primary prevention, stable coronary artery disease, acute coronary syndromes, ischaemic stroke and transient ischaemic attack, peripheral artery disease, atrial fibrillation, and venous thromboembolism). Finally, we summarize the improvements in cardiovascular outcomes observed with the latest glucose-lowering drugs, and on the basis of the available evidence, we expand and integrate current guideline recommendations on antithrombotic strategies in patients with diabetes for both primary and secondary prevention of cardiovascular disease.

Prevention of atherothrombotic events in patients with diabetes mellitus. From antithrombotic therapies to new-generation glucose-lowering drugs / Patti, Giuseppe; Cavallari, Ilaria; Andreotti, Felicita; Calabrò, Paolo; Cirillo, Plinio; Denas, Gentian; Galli, Mattia; Golia, Enrica; Maddaloni, Ernesto; Marcucci, Rossella; Parato, Vito Maurizio; Pengo, Vittorio; Prisco, Domenico; Ricottini, Elisabetta; Renda, Giulia; Santilli, Francesca; Simeone, Paola; De Caterina, Raffaele. - In: NATURE REVIEWS. CARDIOLOGY. - ISSN 1759-5002. - 16:2(2019), pp. 113-130. [10.1038/s41569-018-0080-2]

Prevention of atherothrombotic events in patients with diabetes mellitus. From antithrombotic therapies to new-generation glucose-lowering drugs

Galli, Mattia;Maddaloni, Ernesto;
2019

Abstract

Diabetes mellitus is an important risk factor for a first cardiovascular event and for worse outcomes after a cardiovascular event has occurred. This situation might be caused, at least in part, by the prothrombotic status observed in patients with diabetes. Therefore, contemporary antithrombotic strategies, including more potent agents or drug combinations, might provide greater clinical benefit in patients with diabetes than in those without diabetes. In this Consensus Statement, our Working Group explores the mechanisms of platelet and coagulation activity, the current debate on antiplatelet therapy in primary cardiovascular disease prevention, and the benefit of various antithrombotic approaches in secondary prevention of cardiovascular disease in patients with diabetes. While acknowledging that current data are often derived from underpowered, observational studies or subgroup analyses of larger trials, we propose antithrombotic strategies for patients with diabetes in various cardiovascular settings (primary prevention, stable coronary artery disease, acute coronary syndromes, ischaemic stroke and transient ischaemic attack, peripheral artery disease, atrial fibrillation, and venous thromboembolism). Finally, we summarize the improvements in cardiovascular outcomes observed with the latest glucose-lowering drugs, and on the basis of the available evidence, we expand and integrate current guideline recommendations on antithrombotic strategies in patients with diabetes for both primary and secondary prevention of cardiovascular disease.
2019
diabetes; thrombosis; cardiovascular events; antithrombotic drugs
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Prevention of atherothrombotic events in patients with diabetes mellitus. From antithrombotic therapies to new-generation glucose-lowering drugs / Patti, Giuseppe; Cavallari, Ilaria; Andreotti, Felicita; Calabrò, Paolo; Cirillo, Plinio; Denas, Gentian; Galli, Mattia; Golia, Enrica; Maddaloni, Ernesto; Marcucci, Rossella; Parato, Vito Maurizio; Pengo, Vittorio; Prisco, Domenico; Ricottini, Elisabetta; Renda, Giulia; Santilli, Francesca; Simeone, Paola; De Caterina, Raffaele. - In: NATURE REVIEWS. CARDIOLOGY. - ISSN 1759-5002. - 16:2(2019), pp. 113-130. [10.1038/s41569-018-0080-2]
File allegati a questo prodotto
File Dimensione Formato  
Patti_Atherothrombotic-events_2019.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.41 MB
Formato Adobe PDF
1.41 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1276346
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 80
  • ???jsp.display-item.citation.isi??? 72
social impact